Division of Cardiovascular Surgery, Department of General Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota.
Ann Thorac Surg. 2013 Dec;96(6):2161-7. doi: 10.1016/j.athoracsur.2013.07.004. Epub 2013 Sep 12.
Because no series has specifically analyzed the impact of preoperative atrial fibrillation (AF) on patients already at higher risk of thromboembolism after implantation of a left ventricular assist device (LVAD), we review our experience with these patients.
Between July 2003 and September 2011, 389 patients (308 male) underwent implantation of a continuous flow LVAD at University of Michigan Hospital and Mayo Clinic. Median age at implant was 60 years (range, 18 to 79 years). Preoperative AF was present in 120 patients (31%). Outcomes were analyzed for the association of preoperative AF and postoperative thromboembolic (TE) events defined as stroke, transient ischemic attack, hemolysis, or pump thrombosis. Thromboembolic events occurring within the first 30 days were not counted.
One hundred thirty-eight TEs events occurred in 97/389 patients (25%) for an event rate of 0.31 TE events/patient-years of support. Freedom from a TE event in patients with preoperative AF was 62% at 1 year and 46% at 2 years compared with 79% and 72% at 1 and 2 years, respectively, in patients without preoperative AF (p < 0.001). Median survival was 10 months (maximum 7.2 years, total 439 patient-years). Preoperative AF did not decrease late survival at 1 and 2 years after LVAD implant (preop AF: 85% and 70% versus no preop AF: 82% and 70%, respectively; p = 0.55).
Patients with preoperative AF have a lower freedom from TE events after LVAD implant. While overall late survival was not significantly reduced in these patients, refinement in anticoagulation strategies after VAD implant may be required.
由于没有研究专门分析左心室辅助装置(LVAD)植入后已经存在较高血栓栓塞风险的患者术前心房颤动(AF)的影响,我们回顾了这些患者的经验。
2003 年 7 月至 2011 年 9 月,在密歇根大学医院和梅奥诊所共有 389 名患者(308 名男性)植入连续流 LVAD。植入时的中位年龄为 60 岁(范围,18 至 79 岁)。术前 AF 存在于 120 名患者(31%)中。分析了术前 AF 与术后血栓栓塞(TE)事件的关联,定义为中风、短暂性脑缺血发作、溶血或泵血栓形成。植入后 30 天内发生的 TE 事件不计入。
97/389 名患者(25%)共发生 138 次 TE 事件,每例患者年支持事件发生率为 0.31。术前有 AF 的患者在 1 年和 2 年时无 TE 事件的比例分别为 62%和 46%,而术前无 AF 的患者分别为 79%和 72%(p<0.001)。中位生存时间为 10 个月(最长 7.2 年,总 439 例患者年)。术前 AF 并未降低 LVAD 植入后 1 年和 2 年的晚期生存率(术前 AF:85%和 70%与无术前 AF:82%和 70%,p=0.55)。
术前有 AF 的患者在 LVAD 植入后发生 TE 事件的几率较低。尽管这些患者的总晚期生存率没有显著降低,但可能需要在 VAD 植入后对抗凝策略进行细化。